941 studies (2 from unattributed sources) on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Polaris Peptides | 26 | 99.51% | View COA → |
| Qingdao Sigma Chemical | 23 | 99.51% | View COA → |
| Peptide Sciences | 21 | 99.71% | View COA → |
| Nexaph | 18 | 98.41% | View COA → |
| Simple Peptide | 16 | 99.86% | View COA → |
| Peptide Crafters | 16 | 99.8% | View COA → |
| (unknown) | 16 | 99.57% | View COA → |
| Aminos Research | 15 | 99.73% | View COA → |
Recent certificates: #63635 (99.885%) · #62991 (99.9%) · #42777 (99.91%) · #22090 (99.8%) · #22091 (99.7%) · #14540 (99.9%)
Manufacturers with published third-party certificates of analysis for Semaglutide. Open a vendor to see every batch we've verified.
Early perinatal intervention with **semaglutide** could represent a groundbreaking strategy to break the intergenerational cycle of metabolic disease, potentially reducing the lifelong risk of **obesity**, **type 2 di…
GLP-1RAs and GIP/GLP-1RAs were prescribed to **23.4%** of elderly Japanese **Type 2 Diabetes** patients, frequently alongside other glucose-lowering drugs requiring special caution.
This study provides **compelling real-world evidence for a combined injectable strategy** to effectively counteract the aesthetic side effects of GLP-1RA-induced weight loss. For individuals experiencing facial volume…
**Combination therapy, particularly with GLP-1RAs like semaglutide, should be considered a front-line strategy for pediatric obesity management.** This research provides strong evidence that integrating pharmacotherap…
A new MGH study will investigate how genetic variations influence the metabolic response to **oral semaglutide** after a 14-day treatment and mixed meal tolerance tests.
This study provides compelling evidence that **semaglutide may offer a novel adjunctive therapy for improving psychiatric stability in patients with bipolar disorder who also have diabetes and/or obesity.** For clinic…
This study provides critical evidence that **semaglutide 2.4 mg sustains objective reductions in caloric intake over 60 weeks**, a key mechanism for long-term weight management, even if subjective feelings of appetite…
This large real-world study provides compelling evidence that **semaglutide may offer superior benefits over SGLT2 inhibitors for MASLD patients** across a spectrum of critical outcomes. For clinicians and individuals…
This meta-analysis clarifies that while GLP1-RAs improve the *relative* proportion of lean mass, they still lead to an *absolute* reduction in muscle mass during weight loss. **This finding reframes lean mass loss not…
This systematic review is critical for **GLP-1 RA** users and clinicians, as it addresses a significant gap in understanding the pulmonary safety of these widely prescribed medications. By synthesizing existing eviden…
This preclinical study provides important insights for individuals using semaglutide for chronic weight management, particularly regarding potential long-term effects on bone health. **Clinicians and patients should b…
This study provides compelling preclinical evidence for **Semaglutide** as a potential therapeutic agent for **idiopathic pulmonary fibrosis (IPF)**, a devastating disease with limited options. The identified mechanis…
This modular PEG scaffold fundamentally changes how multi-agonist peptides can be developed, offering a significant leap forward for peptide users and biohackers interested in novel therapeutic combinations. **The pla…
**A novel combination of GLP-1 and amylin agonism could offer superior metabolic control for type 2 diabetes patients.** If successful, CagriSema could provide a more potent and comprehensive treatment option than exi…
If successful, this study will confirm that a new semaglutide formulation and pen-injector are bioequivalent to the existing, prescribed version. **This ensures that patients switching to or starting with the new vers…
While specific results are not detailed, the successful completion of a Phase 1 trial investigating **oral semaglutide** is a crucial step in its development. If the safety and pharmacokinetic profiles prove favorable…
If successful, this trial could establish a groundbreaking strategy for **T1D beta-cell preservation** by combining immunomodulation with metabolic support. The AS01B adjuvant system in Shingrix aims to promote `regul…
While specific findings are absent from this abstract, the *premise* of investigating **GLP-1RA** for **DCAN** is highly significant. If positive results emerge from the full study, it could **redefine standard care f…
**Establishing the feasibility of a semaglutide trial for AF is a crucial first step** towards potentially expanding treatment options for **atrial fibrillation** patients with **overweight** or **obesity**. If a larg…
**Semaglutide's potential to improve psoriasis in T2DM patients offers a dual-benefit therapeutic strategy.** For individuals managing both conditions, this could mean a single medication addresses metabolic health an…
This network meta-analysis provides critical evidence for clinicians treating **childhood and adolescent obesity**, indicating that **semaglutide** offers superior efficacy for **pediatric weight management**, potenti…
This meta-analysis provides reassuring evidence for individuals using **GLP-1 RAs** for **T2DM** or **obesity**, suggesting these medications do not significantly increase the risk of major ocular complications like `…
**Choosing reputable sources for follow-on semaglutide peptides is paramount**, as manufacturing variability directly impacts product quality, stability, and potential immunogenicity. This review underscores that user…
This real-world data provides crucial insights into the practical application and patient experience with **semaglutide 2.4 mg**, moving beyond controlled clinical trial settings. **High patient satisfaction and adher…
This computational trial provides crucial insights for optimizing aesthetic protocols for individuals undergoing GLP-1RA-induced weight loss. **Initiating semaglutide approximately 3 months prior to non-invasive skin …
This study provides crucial clarity for clinicians and individuals using semaglutide, particularly those with **CKD**. It demonstrates that while semaglutide effectively reduces both fat and lean body mass, these body…
**Clinicians and individuals using semaglutide for weight loss should prioritize comprehensive assessments beyond just scale weight.** This reflection underscores that while GLP-1 agonists are effective for weight red…
Semaglutide initiation significantly reduced adult-onset seizure risk by 56% vs other GLDs and 52% vs SGLT2i in patients with type 2 diabetes.
This meta-analysis provides compelling evidence that **weight-lowering drugs** like **orlistat** and **semaglutide** can significantly improve **natural fertility outcomes** in women with overweight or obesity. For cl…
The approval of **resmetirom** and **semaglutide** marks a pivotal shift in **MASH** management, offering the first pharmacological options for a disease previously lacking targeted treatments. **For clinicians and bi…
This trial is crucial for understanding how to optimize outcomes for older adults with **Type 2 diabetes** and **obesity** on **Semaglutide**, particularly regarding muscle preservation. If successful, it could lead t…
**Tirzepatide** combined with laparoscopic sleeve gastrectomy is being investigated for efficacy and safety in severe obesity management over 6 months.
If **semaglutide** demonstrates comparable or superior efficacy to **insulin glargine** with a favorable safety profile, it could significantly impact treatment strategies for **type 2 diabetes**. **Semaglutide** offe…
This real-world analysis provides crucial validation for the SELECT trial's findings, demonstrating that the high cardiovascular risk observed in the trial cohort is consistent with real-world populations. **Semagluti…
This research significantly expands our understanding of **semaglutide's** therapeutic scope, demonstrating its potential as a disease-modifying agent for **osteoarthritis** beyond its known metabolic effects. The ide…
This systematic review highlights that **semaglutide-associated kidney injury, though rare, is a documented adverse event that clinicians and users should be aware of**. The occurrence at standard doses and in patient…
This analysis provides compelling evidence that **IcoSema offers superior postprandial glucose control** compared to other insulin regimens, a critical factor for managing **T2D** and reducing long-term complications.…
This finding offers some reassurance for individuals with **optic disc drusen**, **type-2-diabetes**, or **obesity** who are considering or currently using GLP-1 receptor agonists, suggesting that these medications ma…
This research provides critical real-world evidence suggesting that not all GLP-1 receptor agonists offer identical benefits for kidney outcomes in **Type 2 Diabetes** patients. **Clinicians may consider semaglutide a…
This updated guidance provides a clearer roadmap for clinicians and patients navigating **MASLD**, particularly in primary care. **The emphasis on early, two-step noninvasive fibrosis screening using tools like the Fi…
Semaglutide's neuroprotective and anti-inflammatory potential is being investigated in idiopathic Parkinson's disease.
This pilot trial could establish **semaglutide** as a dual-action therapeutic for obese patients with **psoriasis**, addressing both metabolic and inflammatory aspects. If successful, it would provide a novel, non-imm…
This exploratory study represents an important step in identifying potential next-generation therapies for **obesity** and **overweight**. By evaluating **NNC0165-1875** both as a monotherapy and in combination with t…
**Real-world data on oral semaglutide is crucial** for understanding its effectiveness and tolerability outside of controlled clinical trials. If positive, this study could inform clinicians and patients in the UK abo…
**Wegovy** (semaglutide) is a highly effective treatment for **obesity**, and its increasing use among women of reproductive age makes robust pregnancy safety data critically important. This prospective registry aims …
If successful, this study could significantly refine current **semaglutide weight loss protocols** by demonstrating a clear benefit of concurrent protein supplementation. **Integrating protein supplementation could be…
This study provides crucial real-world evidence supporting **semaglutide** as an effective and well-tolerated option for managing **antipsychotic-induced weight gain (AIWG)** and associated metabolic dysfunction in in…
**This meta-analysis provides reassuring evidence regarding the long-term safety of semaglutide concerning pancreatic cancer risk**, which has been a persistent concern for `GLP-1 RA` users. While a signal for **pancr…
This real-world data confirms that **lower doses of semaglutide (0.5 mg or 1.0 mg)** can achieve clinically meaningful weight loss in Chinese adults with obesity, similar to higher doses seen in trials. This finding i…
**Semaglutide** statistically improves patient-reported physical function and weight-related quality of life in adults with **overweight** or **obesity**. However, **clinicians should communicate these average functio…
Free, no account — handy when you're working with Semaglutide.